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Abstract: Background: Since they’re rare, the intraventricular neoplasms “central 
neurocytoma” best management got diverse, and mystifying. Aim of the work: to assess 
outcome for patients with central neurocytoma and value of specific factors like tumor 
size, surgical resection extent, atypia, and concomitant other modality of treatments by 
radiotherapy in their survival. Patients & methods: 14 patients (8 males, 6 females) were 
managed surgically between 2012 and 2016. They were assessed clinically, radiologically 
and their outcome in relation to selected factors. Results: Median age at diagnosis was 
28.3 years in average (range 16–58). Median follow-up was 32.2 months.we lost 2 cases 
to follow-up in post-operative period. Six patients had recurrent of neurocytoma 
tumours.Five patients (35.7 %) obtained gross total resections (GTR) while 9 patients 
(64.2 %) had subtotal resections (STR). Two STR patients (14.2 %) received dose of 
radiation post operatively that significantly enhanced overall PFS (p =0.047). our series 
data propose that radiation therapy following (STR) usually increase (PFS). Two patients 
proved to have atypical neurocytoma by pathological reports died at 2.3 and 10.2 months 
after the microsurgical procedures. MIB-1 tagging index higher than 4 % is an indicator 
for poor outcome. We used Kaplan–Meier beside Cox proportional hazards methods in 
determining the Progression-free survival (PFS) in our study. Conclusion: the extent of 
surgical resection may improve the neurological condition but not the survival, Atypia 
was the most important factor determine the recurrence & survival while radiotherapy 
improve the survival quietly.  
Key words: Atypical Central neurocytomas, Benign central nervous system tumor, 
Central neurocytomas, MIB-1 tagging index, Progression free survival 
 
Introduction 
Central neurocytoma (CN) is an 
uncommon central nervous system tumor 
which encompass only 0.1–0.5 % of all primary 
brain tumors. It was firstly described by 
Hassoun and colleagues in 1982 and, by the 
early 1990s; it had become a well-defined 
clinical and pathological entity [8]. It was 
classified by the World Health Organization in 
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the year of 2000 A.D. as grade II but malignant 
variant have been reported [13]. However only 
not more than one thousand patients with CN 
have been stated worldwide [10]. Earlier 
studies showed that CN derived from 
ectodermal/nervous system tissue and mainly 
located in deep mid-line structures near the 
foramen of Monro (so it can arise from the 
walls of the lateral ventricles, fornix, the 
septum pellucidum), it is typically situated 
supratentorially filling the lateral ventricle(s) 
and/or the third ventricle with evolving of 
neurological symptoms related to intracranial 
hypertension (headaches beside plus or minus 
visual disturbances. The clinical symptoms 
period usually not more than 6 months [25]. 
Neurocytomas may be found away from the 
ventricles and have been defined by WHO as 
an extraventricular neurocytomas (EVNs). 
This extraventricular neurocytomas (EVNs) 
beside its different places, it have a broader 
scope in morphology compared with 
intraventricular neurocytomas. [13] CN 
frequently arose in youth period, 70% of CN 
patients present in the third and fourth decade 
of life. Tumor incidence shows no significant 
gender preponderance [3, 15, 24]. In spite of 
most CN were benign and most of the patients 
with CN survived for long time after a gross 
total removal but atypical pathological 
variation have been described and even 
residual tumors parts after surgery may 
transformed to have possibility of more 
malignant features [11, 23]. Surgery is the 
basic traditional treatment for these cases and 
the degree of surgical excision is the major 
element affecting the clinical outcome. 
Furthermore, radiotherapy (RT) can 
efficiently control remaining tumor following 
partial microsurgical removal or in recurrent 
cases [12, 17]. The standard guidelines as a 
stepladder treatment for this neoplasm has not 
so far been recognized, particularly that the 
role of Radiation Therapy after the surgery 
stays debatable [7, 19, 22]. Central 
neurocytomas that possess atypical pathologic 
characteristics act more violently and might be 
associated with high recurrence rate. The 
usage of MIB-1 with specific threshold as an 
objective marker to signifying atypia is 
debatable [4, 9, 21]. MIB-1 marker have been 
used in many studies for grading of 
astrocytoma cases. These studies postulate that 
E3 ubiquitin-protein ligase MIB1 act as an 
enzyme which encoded by the human MIB1 
gene in regulating apoptosis. [16] The clinical 
management of neurocytoma remain unclear, 
In this paper, we discussed the management of 
these cases and investigated whether initial 
tumor size, degree of tumor excision, MIB-1 
tagging index and postoperative dose of 
radiotherapy have impact on clinical outcomes 
or not.  
Patients and methods 
All CN patients were treated at Mansoura 
University hospitals (MUH) between 2011 and 
2016. The patients of our study have the 
following inclusion criteria: (1) primary 
surgery was achieved at MUH, (2) original 
management documents was available, and (3) 
the tumor pathology results were obtainable in 
the patient’s records. All existing cases were 
included in our study regardless the follow-up 
period because of the rarity of this tumor, the 
medical reports were reviewed and the 
demographic, treatment options used and 
outcome data were collected. Tumor size was 
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calculated by using T1 imagines post-contrast 
and T2-weighted brain MRI films in the 3 
orthogonal directions, for the tumor volume 
determination. Degree of tumours excision 
was clarified according to the operative notes 
reviewing and post-operative radiology. Gross 
total resection (GTR) was defined by images as 
complete tumor surgical removal and near-
total excision while all other surgical 
techniques as well as partial resection, biopsy 
with or without cyst aspiration, took in 
account as subtotal resection (STR). Patients 
were followed in post-operative period 
clinically and radiologically (MRI and/or CT) 
during the post-surgical follow-up period. 
Tumor evolution was expressed as ≥25 % 
expansion of the above mentioned radiologic 
tumor volume estimation. Outcomes of 
interest included progression free survival 
(PFS) from the date of primary surgery besides 
overall survival (OS) of the same period.  
Statistical analysis  
The evaluation of (PFS) and (OS) was done 
by using the Kaplan–Meier method. While the 
log-rank test and univariate Cox proportional 
hazards methods were applied to validate the 
following items as prognostic factors, for 
instance: degree of tumor removal, tumor 
volume, MIB-1 tagging index, and 
concomitant postoperative radiotherapy 
through its affection on PFS and OS. We used 
p ≤ 0.05 as Statistical significance threshold in 
our research.  
Results  
Demographic data: A sum of 14 CN 
patients (It showed histological and 
immunohistochemical classical features) were 
treated in our department but only 12 patients 
were alive at time of study (Table 1). 
Two patients were lost to follow-up 
afterward primary surgery but were still 
incorporated in the study. The proportion of 
male to female was 1.3:1. The median age at 
tumor diagnosis was 28.3 years (range 16.2–
58.4 years). All patient suffered from 
manifestation of high ICP and three cases had 
seizures. Radiological results: CT brain of 
these cases showed a well demarcated, iso- or 
faintly hyper dense in the supra tentorial 
intraventricular space. Calcifications have 
been seen in eight cases. Images obtained after 
administration iodide contrast substances 
displayed moderately homogeneous 
enhancement lesions in the images of all cases. 
While Cystic changes appeared in 6 cases. 
MRI images of the cases revealed: large 
heterogeneously enhancing intraventricular 
mass which has a “soap bubble” appearance on 
T2. In all cases and broad attachment to the 
septum pellucidum. Most patients (12 cases) 
had their tumors in the cavity of the lateral 
ventricle, and (2 cases represent 14%) 
experienced midline ventricular lesions. 
The median biggest tumor dimension was 
6.7 cm (vary between 3.8–9.6 cm) on 
preoperative MRI examination. Anterior 
Trans callosal approach (TCA) was selected in 
six cases, and anterior transcortical approach 
(TCO) was selected in eight cases. Five of the 
fourteen cases had GTR, on other hand 64 % 
of CN patients (9/14) had STR. Massive 
intraoperative bleeding is crucial point of 
resectability. All tumors were considered as 
WHO Grade II on histopathologic 
examination. Three of the 14 tumors (21 %) 
were distinguished as atypical on 
neuropathological study. 
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Almost 65 % (9/14) of patients had 
hydrocephalus that mandated the application 
of a ventriculoperitoneal shunt at different 
perioperative durations. One patient who had 
a GTR was given a dose of External Beam 
Radiotherapy (EBRT) while only two cases 
with STR (14.2%) were given radiation therapy 
after primary surgical excision. The remaining 
7 cases did not receive any radiation. 
Outcomes 
Follow-up of the study ranged 10.6–43.8 
months (Median duration was 32.2 months).it 
was found that along the study time period, six 
patients (42 %) developed recurrent or 
progressive disease while the residual cases of 
the study did not. Two cases of mortality in the 
study (14.2 %) were reported. The 2-year PFS 
was 71 % in our research beside predictable 5-
years PFS was 52 % (Table 2). The age and 
gender notably did not influence PFS. As 
regard tumor size, p value was 0.79 which 
statistically significant: PFS for 2-years was 72 
% when tumors size lower or equal to 6.1 while 
it was 76% for tumors size higher than 6.1 cm 
concerning tumor atypia in pathological 
examination & immunohistochemical 
staining, 2-year PFS was 89% for MIB tagging 
higher or equal to 4 versus 49 % for MIB 
tagging below 4% (p = 0.0025). The use of 
radiotherapy following surgery for patients 
with subtotal resection STR showed that the 
overall PFS progress was significant with p= 
0.047. As regard the two mortality cases, one 
happened 2.3 months after surgery due to 
intracranial hemorrhage. While the second 
occurred 10.2 months due to disease 
progression. Notably both patients had high 
tumor atypia in their pathological reports, 
where MIB-1 labeling were 5.9 in the first case 
and 6.7 % in the second case. 
TABLE 1 
Demographic and treatment data 
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TABLE 2 
Progression free survival rates (PFS) in relation to clinical factors 
 
 
Management of cases with progressive course  
Quite a few executive approaches were 
applied for the 6 patients who had CN with 
progressive course or recurrence. Two patients 
(30%) administrated course of chemotherapy. 
First case who was a course of CCNU had good 
radiographic images and stable disease for 2 
years later. The other one was treated with 
temozolomide, and had almost three years of 
stable tumor course before restrained 
progress. Two other cases (30 %) had 
radiosurgery courses. Both showed 
radiographic images proved the effectiveness 
of radiation in control of the tumours 
development on follow ups. The last two 
patients (33 %) had repeat surgery. One of 
them was transferred to urgent surgery as a 
sequelae of intracerebral hemorrhages. The 
surgery did not improve the neurological 
condition of the patient and the patient died 
few days after. 
Case illustration 
First case 29 years old lady complained 
from manifestation of intracranial 
hypertension in the form of sever persistent 
headache not responding to medical treatment 
with blurring of vision frequent vomiting, 
Tinnitus and urination disorder. Imaging 
studies of the brain: 
 C.T. (Figure 1) that show a large lesion 
measuring 9X7X5cm in both lateral 
ventricle & centered on septum 
pellucidum. There are numerous high 
density foci concomitant with tumor 
calcification  
 MRI (Figure 2, Figure 3) revealed large 
minimal enhancing intraventricular mass 
which has a “soap bubble” appearance on 
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T2. It has also broad attachment to the 
septum pellucidum  
 Digital Subtraction Angiography “DSA” 
(Figure 4) show tumor feeder from 
Anterior & posterior choroidal arteries  
 2-deoxy-2[F-18] fluoro-D-glucose 
positron emission tomography “FDG-
PET” (Figure 5) show slight 
accumulation in the left side part of the 
mass (60%) 
 
 
Figure 1 - a Preoperative axial CT images 
demonstrating a large lesion measuring 9X7X5cm in 
both lateral ventricle & centered on septum 
pellucidum 
 
 
Figure 2 - MRI of the same tumor: A A:T1WI, 
B:DWI (axi), C:T1WI+CE(cor), D:T2WI (axi), 
E:T1WI+CE(axi), F:T1WI+CE(sag) 
 
Figure 3 - MRI of the same tumor coronal cuts with 
contrast show the wide connection to septum 
pellucidum 
 
 
Figure 4 - Digital Subtraction Angiography DSA show 
feeder from Anterior & posterior choroidal arteries 
 
 
Figure 5 - 2-deoxy-2[F-18] fluoro-D-glucose 
positron emission tomography FDG-PET show slight 
accumulation in the left side part of the mass (60%) 
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First step was forming Extra Ventricular 
drainage “EVD” through frontal burr whole as 
the patient showed deterioration in conscious 
level GCS was 11/15. The opening pressure 
was 40 cm H2O (Figures 6, 7). 
 
 
Figure 6 - a diagram for the site of frontal burr hole 
for EVD 
 
 
Figure 7 - A.CT Brain (axi): show proximal 
intraventricular catheter of EVD. Opening pressure 
40cmH20. B. CT Brain (axi): after 2 days of EVD insertion 
Surgical procedure detail 
• Transcortical trans ventricular approach 
through middle frontal gyrous. (Figure 
8B) 
• The tumor outside is a dark purple soft 
tumor, the inside is a grayish hard tumor 
with calcification. Tumor removed piece 
meal Identification of Anterior septal 
vein & thalamostriate vein of right lateral 
ventricle (Figure 8C) 
• Identification of the vascular structures 
in the field: Anterior septal vein, 
thalamostriate vein & Internal cerebral 
vein of right lateral ventricle at the end 
stage of tumor resection (Figure 8D,E). 
• Open foramen of Monro 
 
 
Figure 8 - A-E show diagrams of surgical steps in 
resection of CN mass of 29 years old female diagram 
for the site of frontal burr hole for EVD 
 
 
Figure 9 - A-E show microscopic pictures of surgical steps in resection of CN mass of 29 years old female till 
complete removal 
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A. HE stain (×100) B. HE stain (×400) C. GFAP (+) D. Olig2 (-) 
   
 
E. Synaptophysin F. NF (-) G. MIB - 1 (+) 3 %  
Figures 10 - A-G a Microscopic histopathological examination pictures showed: A&B revealed neurocytic tumor 
composed of cells with round to oval nuclei [HE stain (×100), 8 HE stain (×400)]. C. showed positive result for 
GFAP. D. showed negative result for Oligo2.  E. revealed Diffuse immunolabeling for synaptophysin.  F. showed 
negative presence of NF. G  The MIB-1 labelling index was about 3% overall 
 
 
Figure 11 - CT brain (axi) one day post-operative 
showed complete removal of CN tumor & some 
Pneomocephalous 
 
Figure 12 - CT brain (axi) five day post-operative 
showed complete removal of CN tumor & 
Pneomocephalous cessation 
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Figure 13 - MRI brain T1WI (axi) five day post-
operative showed complete removal of CN tumor 
 
 
Figure 14 - MRI brain T1WI+CE (axi) five day post-
operative showed complete removal of CN tumor 
Discussion 
It has been thought- long time ago -that the 
worldwide guidelines for management of CN 
has not been recognized and remain indistinct, 
particularly that the effectiveness of RT after 
tumor surgical removal stays debatable,and 
this idea has been augmented because of 
limited cases.In our study, likewise most 
institutions, we recommend surgical excision 
as first line therapy [19]. Although the 
majority of patients will have good prognosis; 
apparent hazard factors that responsible for 
fair outcome are growing. GTR had better 
results than STR, atypical pathological CN 
have worse local control OS in comparison to 
the tumours with classical pathological 
features, and this has been demonstrated in a 
collective data of more than 400 patients from 
international researches [19]. It is currently 
well recognized that more aggressive behavior 
is coupled with a higher MIB-1 labeling index 
[4, 21]. In our study, only twelve cases had 
pathological smears for MIB-1 
immunohistochemical stain (range = 0.65–7, 7 
%).The recurrent cases possessed a higher 
mean MIB-1 index. Future treatment 
guidelines might integrate MIB-1 results as 
one of other factors that will determine further 
need of adjuvant treatment subsequent to STR 
[14].nevertheless, broadly ‘‘atypical 
neurocytoma’’ as a pathological classification 
term with high MIB-1 values as a sign for more 
worse prognosis stay in doubt. Many 
researches failed to proof any association 
between high MIB-1 value and possibility of 
recurrence. Although in this series, even MIB-
1index value of more than 2 % was not linked 
to worse prognosis [1]. 
One of the early studies to identify the 
relationship between MIB-1 tagging index and 
recurrent possibility assumed higher than 2 % 
as an indicator of more aggressive disease 
course [14, 21]. A higher threshold has been 
anticipated based on A meta-analysis achieved 
on some scientific papers about a decade ago, 
signifying that >3 % is interrelated with 
superior recurrence rates and lower OS [18]. 
In the current study, notably elevated risk of 
progression were found in tumors with 
preliminary MIB-1 indices higher than 4 %. 
This finding make parallel with other studies 
that suggest higher thresholds for definition of 
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atypical pathological features with subsequent 
more aggressive disease course [9]. 
On the other hand many researches failed 
to proof any association between high MIB-1 
value and possibility of recurrence. Although 
in this series, even MIB-1index value of more 
than 2 % was not linked to worse prognosis [1]. 
In spite of the threshold, agreement is 
present that multimodality treatment must be 
chosen for managing those tumors with 
elevated MIB-1 values. The tumours with large 
volumes that expanded aggressively in lateral 
ventricle alone or/and the third ventricle, 
possibly will call for more than single 
operation using anterior or/and posterior 
approaches, as in most scientific papers, the 
neurosurgeons could not accomplish GTR for 
CN patients.This fact denoting the technical 
difficulties in surgical removing of the 
intraventricular tumors like CN. However, in 
this study, the degrees of primary surgical 
excision and lesser primary tumor volume did 
not look to illustrate a relationship with better 
local control. Whereas most previous case 
series [7, 19, 22] stress that partial resection of 
CN tumours linked to high rate of recurrence, 
but this fact is still debatable. A modern series 
of 45 central neurocytoma patients data was 
collected retrospectively, found that a 
favorable patients outcome beside tumor 
control was in patients with lesser mitotic 
values. Meanwhile it did not proof any 
noteworthy distinction in tumor local control 
or patient’s outcome between GTR and STR 
[12]. 
In a new methodical review, resection 
degree was not associated with better local 
control [5]. It should be mentioned here that 
assessment of patients’ survival & quality of 
life variances between STR and GTR is not 
feasible, owing to the relatively limited 
patient’s number in this study. The role of 
post-operative radiation dose in improving 
tumor local control & OS was mentioned 
progressively in many current studies [2]. 
Considering the intrinsic restriction of 
limited cases, our figures advocate more 
favorable tumor local control for patient who 
had been exposed to post-operative poster 
dose of radiotherapy in comparison to those 
patients who did not. The suitable and 
effective management for patients who had 
recurrent CN tumours still uncertain, with 
many alternatives which may be only single 
line of treatment or combined to be more than 
one. This include re-surgery, single or multiple 
sessions of EBRT, gamma knife (SRS) beside 
single or multiple cycles of chemotherapy [3]. 
Similarly, on looking to the current study, the 
management multimodalities highlights the 
diversity of these tumours treatment 
guidelines. Genc et al. have examined 
employment of SRS for patients with 
remaining or relapsed CN tumours in one of 
the largest series and after median period of 
follow up approximately 37 months, they 
reported reduction in tumours volume for 
15/22 patients while the CN tumours size 
remain stable in 6/22 and only a case showed 
disease progression [6]. For lesions with lower 
MIB-1, they described a tendency towards a 
better response; nevertheless, these findings 
remain trivial beside its inherited defect of 
short follow up periods. It was recently found 
that for recurrent or residual tumors 
fractionated EBRT and SRS both represent a 
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sound option and this was based on a 
systematic review that also discovered a trivial 
statistical effect of SRS on enhancement of CN 
residual tumor local control and improvement 
of patients’ outcomes beside inferior 
complications rates [5]. The researchers warn 
that the current evidence is typically low-level. 
This may advocate that the cons and pros of 
both treatment lines maintain to be weighed 
for every patient individually, consequently 
prospective data would be so helpful. We are 
in agreement that the maximal harmless CN 
tumours microsurgical excision still the 
golden standard treatment option. The 
presence of tumor atypia features and high 
MIB-1 label in pathological examination & 
immunohistochemical staining films should 
guide us to give these patient post-operative 
dose of radiation. In more detail, the usage of 
a MIB-1 label value of 4 % as a landmark for 
tumours atypia and disease aggressiveness is 
supported by our study findings and we advise 
co-specialties of concern consultations for 
those patients. On reviewing our study we can 
conclude that the post-operative EBRT could 
diminish the chances of growth for partly 
surgical removed CN tumours. Lastly, SRS as a 
modern treatment modality can be a valuable 
option, especially in recurrent cases. 
Conclusion 
The extent of surgical resection may 
improve the neurological condition but not 
the survival, Atypia was the most important 
factor determine the recurrence & survival 
while radiotherapy improve the survival 
quietly. 
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